Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Inhibrx Biosciences, Inc. · INBX · Third quarter 2026

Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms

A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.

18 Nov 2026 · CompePharma editorial
$2.0 millionQ3 2026 revenue
$38.7 million, or $2.46 per shareQ3 2026 net loss
$26.0 million vs $28.5 million in Q3 2025Q3 R&D expense
$7.8 million vs $5.3 million in Q3 2025Q3 G&A expense
$199.5 millionCash and cash equivalents (Sept. 30, 2026)
$275.0 millionOutstanding loan balance

The quarter in numbers

Inhibrx Biosciences reported third-quarter 2026 revenue of $2.0 million, against none in the third quarter of 2025. The company said the revenue came from a Pfizer licence agreement under which it granted a non-exclusive licence to certain patent rights for a $2.0 million upfront payment, received in September 2026.

Net loss was $38.7 million, or $2.46 per share, basic and diluted. That compares with $35.3 million, or $2.28 per share, a year earlier, an increase of roughly 10%. Weighted shares used in the per-share calculation were 15.72 million, against 15.48 million.

Total operating expenses were almost unchanged at $33.7 million (versus $33.8 million), so the loss from operations narrowed to $31.7 million from $33.8 million. The gap between operating and net loss widened because of financing costs. For the nine months, net loss was $108.8 million ($6.95 per share), against $107.2 million ($6.93).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
Tonix Pharmaceuticals Holding Corp. · TNXP · Third quarter 2026

Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate

approximately $17.2 million (vs $3.3 million in Q3 2025)Net product revenue, Q3 2026approximately $15.0 million, up 37% from Q2TONMYA net sales, Q3 2026$53.3 million, or $2.89 per shareNet loss to common, Q3 2026

Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.

19 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
ADC Therapeutics SA · ADCT · Third quarter 2026

ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH

$21.0 million (vs $15.8 million in Q3 2025)Q3 2026 net product revenue$36.1 million, a 24% reductionQ3 total operating expenses$25.3 million, or $0.16 per share (vs $41.0 million, or $0.30)Q3 net loss

Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.

18 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Talphera, Inc. · TLPH · Third quarter 2026

Talphera's Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close

$4.0 million, or $0.05 per basic and diluted shareQ3 2026 net loss$4.4 million, or $0.11 per basic and diluted shareQ3 2025 net loss$4.1 million vs $3.4 million in Q3 2025Q3 combined R&D and SG&A

With $14.2 million in cash and a pivotal CRRT study running short of its 70-patient target, Talphera is asking the FDA to accept a December 31, 2026 enrollment cutoff.

18 Nov 2026 · CompePharma editorial